Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Karyopharm Therapeutics Inc. (KPTI) had Income from Continuous Operations of $-76.42M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$145.24M |
|
$-76.42M |
|
$6.01M |
|
$139.23M |
|
$264.68M |
|
$-119.44M |
|
$43.08M |
|
$-76.36M |
|
$-76.36M |
|
$-76.42M |
|
|
Income from Continuous Operations |
$-76.42M |
$-76.42M |
|
$-76.42M |
|
$-119.44M |
|
$-115.24M |
|
8.13M |
|
8.46M |
|
$-9.45 |
|
$-13.94 |
|
| Balance Sheet Financials | |
$156.49M |
|
$0.40M |
|
$7.93M |
|
$164.42M |
|
$92.26M |
|
$162.95M |
|
$258.17M |
|
$350.44M |
|
$-186.02M |
|
$-186.02M |
|
$-186.02M |
|
8.42M |
|
| Cash Flow Statement Financials | |
$-127.49M |
|
$95.47M |
|
$41.65M |
|
$53.19M |
|
$62.81M |
|
$9.62M |
|
$18.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.70 |
|
-- |
|
-- |
|
-7.06 |
|
-1.01 |
|
95.86% |
|
-82.24% |
|
-82.24% |
|
-79.34% |
|
-52.58% |
|
-52.62% |
|
$-127.63M |
|
-- |
|
-- |
|
-- |
|
0.88 |
|
1.27 |
|
4.72 |
|
77.32 |
|
41.08% |
|
41.08% |
|
-46.48% |
|
331.28% |
|
$-22.10 |
|
$-15.09 |
|
$-15.07 |
|